Skip to Content
Merck

The allosteric modulation of complement C5 by knob domain peptides.

eLife (2021-02-12)
Alex Macpherson, Maisem Laabei, Zainab Ahdash, Melissa A Graewert, James R Birtley, Monika-Sarah Ed Schulze, Susan Crennell, Sarah A Robinson, Ben Holmes, Vladas Oleinikovas, Per H Nilsson, James Snowden, Victoria Ellis, Tom Eirik Mollnes, Charlotte M Deane, Dmitri Svergun, Alastair Dg Lawson, Jean Mh van den Elsen
ABSTRACT

Bovines have evolved a subset of antibodies with ultra-long heavy chain complementarity determining regions that harbour cysteine-rich knob domains. To produce high-affinity peptides, we previously isolated autonomous 3-6 kDa knob domains from bovine antibodies. Here, we show that binding of four knob domain peptides elicits a range of effects on the clinically validated drug target complement C5. Allosteric mechanisms predominated, with one peptide selectively inhibiting C5 cleavage by the alternative pathway C5 convertase, revealing a targetable mechanistic difference between the classical and alternative pathway C5 convertases. Taking a hybrid biophysical approach, we present C5-knob domain co-crystal structures and, by solution methods, observed allosteric effects propagating >50 Å from the binding sites. This study expands the therapeutic scope of C5, presents new inhibitors, and introduces knob domains as new, low molecular weight antibody fragments, with therapeutic potential.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-Sheep Red Blood Cell Stroma antibody produced in rabbit, fractionated antiserum, lyophilized powder